Nagarajah James, Janssen Marcel, Hetkamp Philipp, Jentzen Walter
Department of Radiology and Nuclear Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; and
Department of Nuclear Medicine, University of Duisburg-Essen, Duisburg, Germany.
J Nucl Med. 2017 Sep;58(Suppl 2):34S-38S. doi: 10.2967/jnumed.116.186866.
Theranostics, a modern approach combining therapeutics and diagnostics, is among the most promising concepts in nuclear medicine for optimizing and individualizing treatments for many cancer entities. Theranostics has been used in clinical routines in nuclear medicine for more than 60 y-as I for diagnostic and therapeutic purposes in thyroid diseases. In this minireview, we provide a survey of the use of 2 different radioiodine isotopes for targeting the sodium-iodine symporter in thyroid cancer and nonthyroidal neoplasms as well as a brief summary of theranostics for neuroendocrine neoplasms and metastatic castration-refractory prostate cancer. In particular, we discuss the role of I-based dosimetry in targeting of the sodium-iodine symporter and describe the clinical application of I dosimetry in a patient who had radioiodine-refractory thyroid cancer and who underwent a redifferentiation treatment with the mitogen-activated extracellular signal-related kinase kinase inhibitor trametinib.
治疗诊断学是一种将治疗与诊断相结合的现代方法，是核医学中最具前景的概念之一，可优化并个性化许多癌症实体的治疗方案。治疗诊断学已在核医学临床常规应用中使用了60多年，例如用于甲状腺疾病的诊断和治疗。在本微型综述中，我们概述了两种不同放射性碘同位素在甲状腺癌和非甲状腺肿瘤中靶向钠碘同向转运体的应用，以及神经内分泌肿瘤和转移性去势抵抗性前列腺癌治疗诊断学的简要总结。特别是，我们讨论了基于碘的剂量测定法在靶向钠碘同向转运体中的作用，并描述了碘剂量测定法在一名放射性碘难治性甲状腺癌患者中的临床应用，该患者接受了丝裂原活化细胞外信号相关激酶激酶抑制剂曲美替尼的再分化治疗。
